PFIZER AND BIONTECH TO GiveU.S. GOVERNMENT AN Fresh 50 MILLION PEDIATRIC Boluses OF COVID-19 VACCINE TO SUPPORT Farther PREPAREDNESS FOR FUTURE NEEDS

PFIZER AND BIONTECH TO GiveU.S. GOVERNMENT AN Fresh 50 MILLION PEDIATRIC Boluses OF COVID-19 VACCINE TO SUPPORT Farther PREPAREDNESS FOR FUTURE NEEDS

PfizerInc. (NYSE PFE) and BioNTech SE (Nasdaq BNTX) moment blazoned that theU.S. government has bought 50 million further boluses of the companies’COVID-19 vaccine. TheU.S. will admit these fresh boluses to continue to support preparedness for pediatric vaccinations, including securing vaccines for children under 5 times of age, should they admit nonsupervisory authorization. The companies anticipate to deliver all these boluses by April 30, 2022.
This press release features multimedia. View the full release then https//www.businesswire.com/news/home/20211028005559/en/

With this order, theU.S. government has exercised its final purchase option under its beingU.S. force agreement with the companies, bringing the total number of Pfizer-BioNTech COVID-19 Vaccine boluses secured under the agreement since the launch of the epidemic to 600 million – gauging boluses for grown-ups and adolescents, and children. Independently, Pfizer and BioNTech have agreed to give a aggregate of 1 billion boluses to theU.S. government at a not-for- profit price for donation to low-and lower- middle- income countries.
PFIZER AND BIONTECH TO GiveU.S. GOVERNMENT AN Fresh 50 MILLION PEDIATRIC Boluses OF COVID-19 VACCINE TO SUPPORT Farther PREPAREDNESS FOR FUTURE NEEDS

PfizerInc. (NYSE PFE) and BioNTech SE (Nasdaq BNTX) moment blazoned that theU.S. government has bought 50 million further boluses of the companies’COVID-19 vaccine. TheU.S. will admit these fresh boluses to continue to support preparedness for pediatric vaccinations, including securing vaccines for children under 5 times of age, should they admit nonsupervisory authorization. The companies anticipate to deliver all these boluses by April 30, 2022.
This press release features multimedia. View the full release then https//www.businesswire.com/news/home/20211028005559/en/

With this order, theU.S. government has exercised its final purchase option under its beingU.S. force agreement with the companies, bringing the total number of Pfizer-BioNTech COVID-19 Vaccine boluses secured under the agreement since the launch of the epidemic to 600 million – gauging boluses for grown-ups and adolescents, and children. Independently, Pfizer and BioNTech have agreed to give a aggregate of 1 billion boluses to theU.S. government at a not-for- profit price for donation to low-and lower- middle- income countries.
“ We’re extremely proud to give enough boluses of our vaccine to help cover everyU.S. child under 12 from COVID-19, if authorized by the FDA,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “ As we await the agency’s review of our operation for exigency use of the vaccine in children 5 to under 12 times of age, and clinical trial results in children under 5, we’re working with theU.S. government to help insure communities across the country have access to pediatric boluses as soon as possible. The preface of boluses for youthful children will be another critical corner in addressing this public health extremity.”

“ From the veritably morning, it has been our thing to give access to a largely effective vaccine to as numerous people as possible. This force agreement will help to offer a vaccine to all children youngish than 12 times of age in the United States,” said Ugur Sahin, CEO andCo-founder of BioNTech. “ We’d like to thank theU.S. government for its trust in us and our vaccine.”
Pfizer and BioNTech submitted a request before this month to theU.S. Food and Drug Administration (FDA) for Exigency Use Authorization of their COVID-19 vaccine in children 5 to< 12 times of age. The lozenge strength for this age group (10 µg) was precisely named as the preferred cure for safety, tolerability and immunogenicity, and differs from the lozenge strength for individualities 12 times and aged (30 µg). If authorized and latterly recommended by theU.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), the companies anticipate to also begin dispatching 10-µg pediatric boluses incontinently, as directed by theU.S. government. EligibleU.S. residers will continue to admit the vaccine for free, harmonious with theU.S. government’s commitment to free access to COVID-19 vaccines.

In addition to theU.S. FDA, the companies have submitted data to the European Medicines Agency to support the vaccination of children 5 to< 12 times of age. Farther cessions for this age group are planned or underway with other nonsupervisory agencies around the world. Original data from the other two age cohorts in the ongoing Pfizer-BioNTech clinical trial in children – those 2 to< 5 times of age and those 6 months to< 2 times of age – are anticipated as soon as fourth quarter 2021 or beforehand first quarter 2022.
Commitment to Global Vaccine Access

In aggregate, Pfizer and BioNTech anticipate to manufacture 3 billion boluses of their COVID-19 vaccine worldwide in 2021, which includes pediatric boluses. In 2022, the companies anticipate to manufacture 4 billion boluses of the Pfizer-BioNTech COVID-19 Vaccine worldwide, which also includes pediatric boluses. The companies don’t anticipate the preface of pediatric boluses in theU.S. to impact the being force agreements in place with governments and transnational health associations around the world.
To date, Pfizer and BioNTech have packed further than1.8 billion COVID-19 vaccine boluses to 149 countries and homes. The companies are forcefully committed to working toward indifferent and affordable access for COVID-19 vaccines and have pledged to give 2 billion boluses to low-and middle- income countries in 2021 and 2022 – at least 1 billion each time.

The Pfizer-BioNTech COVID-19 Vaccine, which is grounded on BioNTech’s personal mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of exigency use authorizations or coequals in the United States ( concertedly with Pfizer) and other countries. Cessions to pursue nonsupervisory blessings in those countries where exigency use authorizations or original were originally granted are planned or ongoing.
U.S INDICATION & AUTHORIZED USE